

# Sanlam Stable Global Fund

Q1 2019 | Quarterly newsletter

## Market recap

The first quarter of 2019 has been an exceptionally strong quarter with the MXWO Index up in USD by +11.8% which is the best quarterly return since September 2010. This was largely driven by strong performance in the US markets with the S&P 500 rising by +14.4%. January saw a very robust rebound from the prior quarter with strong jobs data in the US, Powell's diligence in communicating a dovish approach to the markets, positive US-China trade talks and a rebound in oil prices. This positivity carried on into February and March with the price of oil climbing towards \$70 a barrel as OPEC cuts alter the supply-demand landscape. However, there were negative economic reports showing low growth with expectations Germany may experience a recession shortly and poor business confidence in the EU while weak housing data and consumer confidence reports were reported in the US.

Other notable events during the quarter included the US three month and ten year treasury spreads inverting which has historically been the best predictor of recessions having forecast seven of the last seven downturns. Vale shuttered its Brucutu mine due to the death of approximately 300 people which has kept metal prices well supported. Brexit remains unresolved with Theresa May struggling to make progress and the EU granting an extension to October 31st as long as Britain participates in the EU elections.

Over the quarter the two top performing sectors were Information Technology (+19.7%) and Real Estate (+16.3%) with Health Care (+8.4%) and Financials (+8.6%) being the worst two performers.

## Fund review

In a rising market, the fund outperformed the CPI target but underperformed the broader equity markets. The defensive nature of the fund led to the underperformance with both allocation and stock selection being negative detractors.

Healthcare detracted the most with Cigna and UnitedHealth performing poorly on political concerns that Medicare and Medicaid spending could be cut.

## Performance data

	Inception	QTR	YTD	1yr	3yrs	5yrs	Since Inception
B Accumulation USD	10/09/12	9.6	9.6	7.7	6.2	6.0	10.0
MSCI ACWI - USD		12.2	12.2	2.6	10.7	6.4	9.0
CPI +6%		1.6	1.6	7.5	8.2	7.4	7.6
A Accumulation USD	18/10/13	9.4	9.4	6.9	5.4	0.1	6.1
MSCI ACWI - USD		12.2	12.2	2.6	10.7	0.1	6.8
A Accumulation GBP	02/01/15	6.9	6.9	15.0	9.0	n/a	8.9
MSCI ACWI - GBP		9.6	9.6	10.5	14.4	n/a	11.2

Performance beyond one year is annualised

12 Months to	Mar-19	Mar-18	Mar-17	Mar-16	Mar-15
B Accumulation USD	7.7	1.8	9.3	1.1	10.3
A Accumulation USD	6.9	1.0	8.5	0.4	9.5
MSCI ACWI - USD	2.6	14.8	15.0	-4.3	5.4
CPI +6%	7.5	8.2	8.8	7.0	5.8
A Accumulation GBP	15.0	-10.2	25.5	3.1	-
MSCI ACWI - GBP	10.5	2.4	32.2	-1.2	-

Past performance is not an indicator of future performance.

Source: Sanlam, Morningstar and Lipper as at 31/03//2019.

## Key facts

<b>Fund AuM</b>	\$80.0m
<b>Strategy AuM</b>	\$80.0m
<b>Number of Holdings</b>	27
<b>Active Share</b>	92.8%
<b>Portfolio Yield*</b>	2.7%
<b>Fund Managers</b>	Colin McQueen
<b>Target</b>	CPI +6%
<b>Fund Launch Date</b>	10 September 2012
<b>Domicile</b>	Ireland
<b>Base Currency</b>	US Dollar
<b>Fund Type</b>	OEIC, UCITS V
<b>IA Sector</b>	Global
<b>Morningstar Category</b>	Global Large-Cap
<b>Dealing Deadline</b>	14:00 (GMT)
<b>Settlement Time</b>	T+3
<b>Valuation Point</b>	23:59 (GMT)
<b>Distribution</b>	Quarterly

\*Portfolio yield is calculated by adding the net dividend amounts for all dividend types that have gone 'ex' over the past 12 months based on the dividend frequency.

## Performance attribution

Over the quarter, the fund generated a 9.6% return in USD, which falls short of the 12.2% of the MSCI World, but is above the fund's objective of CPI+6%.

The main detractors were, on one hand, the lack of exposure to high-growth Tech names (FAANGs in particular) which outperformed the market significantly, and on the other, the fund's heavy exposure to the Healthcare sector.

The healthcare names were both the victim of political sentiment, as democrats proposed in February the "Medicare for All" bill aimed at galvanizing the party's liberal base. The DoJ's support for Texas's ruling of the ACA being unconstitutional was another troubling headline that could put into doubt future volumes for the PBMs and Distributors. However, at this stage any significant price reaction is immensely premature as the probability of any change is exceedingly low.

Cigna and United Health were the Healthcare names that had the largest impact on our portfolio.

On the positive side, EBAY (+142bps) and Oracle (+91bps) were the top contributors.

EBAY has been one of our core holdings for a long time, but it has only been recently that the market seemed to realise what we had long been saying: e-commerce is not only Amazon, and EBAY covers a specific demand (delisted/used parts or items) where it is the absolute leader. What triggered the market's reaction was the news that an activist investor (Elliot Management) had made some proposals to management that, if implemented, could lead to shares being overvalued by ~100%.

## Outlook

With the broader equity market trading at or above its long term average valuation, it is difficult to claim equities as a group are cheap. In fact we would argue that after a decade of low inflation aided by US tax cuts, a healthy consumer environment and cheap credit, the market multiples have in all likelihood an inflated denominator. Corporate profit margins, particularly in the US, have never been higher and the cost of debt has rarely been this low.


While we are always wary of leverage, thinking about the next 3 to 5 years we would be particularly careful in getting into investments that make liberal use of debt combined with high operating leverage. The unwinding of this relationship could be disastrous.

As always, we do not claim to have a particular edge in predicting the macro environment, but the slowing interest rate schedule in the US and renewed monetary commitment in Europe, as well as heightened geopolitical tensions, makes us wary to invest in anything that at its core has a binomial macro outcome.

As a result we will continue focusing on bottom up, fundamental analysis, selecting companies that we think are obviously undervalued and whose future is largely under their own control. Protection of capital is and remains our primary concern.

While markets overall do not appear particularly cheap, the spread of valuation between in-favour and out-of-favour stocks remains significant. Just think of how anything with "subscription" in the description trades at minimum 25x earnings, and how everything else perceived as old tech or discretionary trades in the teens or lower. As value investors we will continue looking at both camps and find large disconnects between market perception and reality while always remaining faithful to our conservative projections.

### Top 5 Stock Contributors and Detractors



Source: Bloomberg as at 31/03/2019.

Regarding Oracle, there has not been a clear catalyst for its >20% rally, but we are pleased that the stock is now even above its peak level in 2018, and feel that the market is starting to fully appreciate the tremendous economics of this business as it transitions from its traditional software licence model towards a SaaS model.

## Contact us

Liz Adnitt  
Sales Director

+44 (0) 20 3116 4071  
Liz.Adnitt@Sanlam.co.uk

Alexandra Dacres-Hogg  
Sales Manager

+44 (0) 20 3116 4041  
Alexandra.Dacreshogg@Sanlam.co.uk

Sanlam Investments  
Monument Place  
24 Monument Street  
London  
EC3R 8AJ

## Important Information

The Fund has holdings which are denominated in currencies other than sterling and may be affected by movements in exchange rates. Consequently the value of an investment may rise or fall in line with the exchange rates. The Fund holds a concentrated portfolio which could mean that it will be volatile when compared to its benchmark.

The value of this portfolio is subject to fluctuation and past performance is not necessarily a guide to future performance. The performance is calculated for the portfolio and the actual individual investor performance will differ as a result of initial fees, the actual investment date, the date of reinvestment and dividend withholding tax. All terms exclude costs. Fluctuations or movements in exchange rates may cause the value of underlying investments to go up or down. Do remember that the value of participatory interests or the investment and the income generated from them may go down as well as up and is not guaranteed, therefore, you may not get back the amount originally invested and potentially risk total loss of capital. Therefore, the Manager does not provide any guarantee either with respect to the capital or the return of a portfolio. The Manager has the right to close any Portfolios to new investors to manage them more efficiently in accordance with their mandates. Collective Investment Schemes are traded at ruling prices and can engage in borrowing and scrip lending. Collective Investment Schemes (CIS) are generally medium to long term investments. A schedule of fees and charges and maximum commissions is available on request free of charge from the Manager, the Investment Manager or at [www.sanlam.ie](http://www.sanlam.ie).

Issued and approved by Sanlam Investments. Sanlam Investments is the trading name for our two Financial Conduct Authority (FCA) regulated entities: Sanlam Investments UK Limited (FRN 459237), having its registered office at 24 Monument Street, London, EC3R 8AJ and Sanlam Private Investments (UK) Ltd (FRN 122588) having its registered office at 16 South Park, Sevenoaks, Kent, TN13 1AN.

The Fund is a sub-fund of the Sanlam Universal Funds plc, a company incorporated with limited liability as an open-ended umbrella investment company with variable capital and segregated liability between sub-funds under the laws of Ireland and authorised by the Central Bank. The Fund is managed by Sanlam Asset Management (Ireland) Limited, Beech House, Beech Hill Road, Dublin 4, Ireland, Tel + 353 1 205 3510, Fax + 353 1 205 3521 which is authorised by the Central Bank of Ireland, as a UCITS Management Company and Alternative Investment Fund Manager, and is licensed as a Financial Service Provider in terms of Section 8 of the South African FAIS Act of 2002. Sanlam Asset Management is a registered business name of Sanlam Asset Management (Ireland) Limited. Sanlam Asset Management (Ireland) has appointed Sanlam Investments UK Ltd or Sanlam Private Investments (UK) Ltd as Investment Manager to this fund.

This document is provided to give an indication of the investment and does not constitute an offer/invitation to sell or buy any securities in any fund managed by us nor a solicitation to purchase securities in any company or investment product. It does not form part of any contract for the sale or purchase of any investment. The information contained in this document is for guidance only and does not constitute financial advice.

The fund price is calculated on a net asset value basis, which is the total value of all assets in the portfolio including any income and expense accruals. Trail commission and incentives may be paid and are for the account of the manager. Performance figures quoted are from Sanlam and are shown net of fees. Performance figures for periods longer than 12 months are annualized. NAV to NAV figures are used. Calculations are based on a lump sum investment.

Please note that all Sanlam Funds carry some degree of risks which may have an adverse effect on the future value of your investment. Any offering is made only pursuant to the relevant offering document, together with the current financial statements of the relevant fund, and the relevant subscription/application forms, all of which must be read in their entirety together with the Sanlam Universal Funds plc prospectus, the Fund supplement, and the KIID. All these documents explain different types of specific risks associated with the investment portfolio of each of our products and are available free of charge from the Manager or at [www.sanlam.ie](http://www.sanlam.ie). No offer to purchase securities will be made or accepted prior to receipt by the offeree of these documents, and the completion of all appropriate documentation. Use or rely on this information at your own risk. Independent professional financial advice should always be sought before making an investment decision as not all investments are suitable for all investors.

This document contains information intended only for the person to whom it is addressed or presented (Investment Professionals, defined as Eligible Counterparties or Professional Clients), and is intended for evaluation purposes, with no licence to use the content or materials within. It must not be distributed to general public, or relied upon by Retail Investors.

The opinions are those of the author at the time of publication and are subject to change, without notice, at any time due to changes in market or economic conditions. Whilst care has been taken in compiling the content of this document, neither Sanlam nor any other person makes any guarantee, representation or warranty, express or implied as to its accuracy, completeness or fairness of the information and opinions contained in this document, which has been prepared in good faith, and to the fullest extent permissible under UK law. Some parts/sections of this document may be compiled from external sources. Whilst these sources are believed to be reliable, the information has not been independently verified and is subject to material amendment, revision and updating, therefore no representation is made as to its accuracy or completeness. No reliance may be placed for any purpose whatsoever on the information, representations or opinions contained in this document nor shall it or any part of it form the basis of or act as an inducement to enter into any contract for any securities, and to the fullest extent permissible under UK law no liability is accepted or any such information, representations or opinions. The comments should not be construed as a recommendation of individual holdings or market sectors, but as an illustration of broader themes.

Statements in this document that reflect projections or expectations of future financial or economic performance of a strategy, or of markets in general, and statements of any Sanlam strategies' plans and objectives for future operations are forward-looking statements. Actual results or events may differ materially from those projected, estimated, assumed or anticipated in any such forward-looking statement. Important factors that could result in such differences, in addition to the other factors noted with forward-looking statements, include general economic conditions such as inflation, recession and interest rates, political or business conditions or in the tax or regulatory framework in the UK or other relevant jurisdictions, any of which could cause actual results to vary materially from the future results implied in such forward-looking statements. No assurance can be given as to the future results that will be achieved.

Sanlam makes no representation as to whether any illustration/example mentioned in this document is now or was ever held in any Sanlam Fund or Model Portfolio. Examples / Illustrations shown are only for the limited purpose of analysing general market, economic conditions or highlighting specific elements of the research process.

All of the information herein should be treated as confidential material with no less care than that afforded to the addressee's own confidential material of the most sensitive nature.

Neither Sanlam nor any other person accepts responsibility or liability whatsoever for any loss howsoever arising, either directly or indirectly from any use of this presentation or its contents or otherwise arising in connection therewith. It should not be copied, faxed, reproduced, divulged or redistributed or passed on, directly or indirectly, to any other person or published in whole or in part, for any purpose, without the express written consent of Sanlam.

There is no certainty the investment objectives of the portfolios or strategies mentioned in this document will actually be achieved and no warranty or representation is given to this effect.

Sanlam funds mentioned in this document are only available for sale in certain jurisdictions. For the avoidance of doubt, this document is not intended to promote these Funds to any person in any jurisdiction where such promotion is not permitted under applicable laws and regulations. Potential investors in these Funds should inform themselves of the applicable laws and regulations of the countries of their citizenship, residence or domicile and which might be relevant to any type of transaction in shares/units of our Funds. By accepting the terms of this disclaimer, you expressly acknowledge that you are, as the case may be, an investor who is legally or otherwise duly authorised to seek information about our Funds.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This document is not approved, reviewed or produced by MSCI. SAH0419(52)0719UKInst